RFA provides sustained pain relief in osteoid osteoma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 3
Volume 17
Issue 3

CT-guided radiofrequency ablation (RFA) offers long-term pain reduction in patients with osteoid osteoma, making RFA a viable alternative to open surgery, according to researchers from Seoul, South Korea.

SAN FRANCISCO-CT-guided radiofrequency ablation (RFA) offers long-term pain reduction in patients with osteoid osteoma, making RFA a viable alternative to open surgery, according to researchers from Seoul, South Korea.

“Surgery is considered if pain persists, but open surgical excision is known to have high morbidity, and recurrence is not uncommon,” Ki Sun Sung, MD, PhD, said at the 2007 American Academy of Orthopedic Surgeons meeting (abstract 464). Dr. Sung and his co-authors are from Sungkyunkwan University School of Medicine and Samsung Medical Center.

This retrospective study focused on 28 patients, between 1995 and 2005, with osteoid osteoma, all of whom did not respond to conservative treatment with anti-inflammatory drugs. Patients underwent RFA and had at least 2 years of follow-up data available. Of the 28 patients, 26 had primary tumors and two had recurring disease. The nidus size ranged from 2 to 14 mm in diameter. During CT-guided RFA, the lesion was heated to 80 to 90 C for an average of 6.5 minutes.

RFA was deemed technically successful in 27 cases. There was one skin burn complication. All patients were discharged 1.8 days after the procedure. At 2 years post-RFA, 90% of patients said they had a complete loss of symptoms. An additional RFA procedure was required in three subjects for a recurrence rate of about 10%. These patients said they had pain relief after the second treatment. All patients remained symptom free 6 years after RFA.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content